Key result
NID2 overexpression increases atherosclerotic plaque area by ~74% in preclinical models.
Why the study?
Understanding molecular mechanisms linking NAFLD and ASCVD is critical for developing therapies targeting both simultaneously, following preliminary findings of elevated nidogen 2 expression in human atherosclerotic tissues and murine steatotic livers.
Does NID2 overexpression promote hepatosteatosis and atherosclerosis in Apoe-/- mice fed a Western diet?
Does NID2 overexpression promote hepatosteatosis and atherosclerosis in Apoe-/- mice fed a Western diet?
NID2 overexpression exacerbates both hepatosteatosis and atherosclerosis in a murine model, identifying it as a potential therapeutic target for cardiometabolic diseases.
Answers are grounded in this paper and cite their sources.
NID2 overexpression may exacerbate atherosclerosis in this model; leaves open its relevance as a human cardiometabolic target.
Clinical and genetic studies strongly support a significant connection between nonalcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD) and identify ASCVD as the primary cause of death in NAFLD patients. Understanding the molecular factors and mechanisms regulating these diseases is critical for developing novel therapies that target them simultaneously. Our preliminary immunoblotting experiments demonstrated elevated expression of nidogen 2 (NID2), a basement membrane glycoprotein, in human atherosclerotic vascular tissues and murine steatotic livers. Therefore, we investigated the role of NID2 in regulating hepatosteatosis and atherosclerosis utilizing Western diet-fed Apoe−/− mice with/without NID2 overexpression. Quantitative real-time PCR confirmed increased NID2 mRNA expression in multiple organs (liver, heart, kidney, and adipose) of NID2-overexpressing mice. Male mice with NID2 overexpression exhibited higher liver and epididymal white adipose tissue mass, increased hepatic lipid accumulation, and fibrosis. Additionally, these mice developed larger atherosclerotic lesions in the whole aortas and aortic roots, with increased necrotic core formation. Mechanistic studies showed reduced AMPK activation in the livers of NID2-overexpressing mice compared with controls, without any effects on hepatic inflammation. In conclusion, these findings suggest that NID2 plays a deleterious role in both hepatosteatosis and atherosclerosis, making it a potential therapeutic target for these conditions.
No takes yet. Share an insight, caveat, or question.
Kathuria et al. (2024) studied Hepatosteatosis and Atherosclerosis. NID2-AAV (Adeno-associated viral vector expressing human NID2) vs. Control (Saline or Control-AAV) was evaluated on Atherosclerotic plaque area in whole aorta via en face ORO staining (74.09% increase). NID2 overexpression significantly increased atherosclerotic plaque area by 74.09% (12.5% vs 7.18%) in male Apoe-/- mice fed a Western diet.
Synapse has enriched 10 related papers. Consider them for comparative context: